Business Wire

Top 10 Finalist Nurses Announced for Inaugural Aster Guardians Global Nursing Award

11.4.2022 16:57:00 EEST | Business Wire | Press release

Share

Aster Guardians Global Nursing Award has just announced its top 10 finalists hailing from across the world. These nurses have been selected from over 24,000 nurses who applied from over 184 countries, through a stringent review process run independently by Ernst & Young LLP, a Screening Jury and a Grand Jury. All applications were evaluated to create a shortlist of 181 which underwent further review to put forward 41 top applications. These 41 applications were then reviewed by the Grand Jury to announce the top 10 finalists. All applicant nurses were asked to submit their applications based on four areas of contribution: Leadership, Research/Innovation, Patient Care and Society/Community Service.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005418/en/

The top 10 finalists, who will now undergo further evaluation to claim the grand prize of USD 250,000, are: Anna Qabale Duba from Kenya; Dida Jirma Bulle from Kenya; Francis Michael Fernando from United Kingdom; Jasmine Mohammed Sharaf from United Arab Emirates; Julia Dorothy Downing from United Kingdom; Lincy Padicala Joseph from India, Manju Dhandapani from India; Matthew James Ball from Australia; Rachel Abraham Joseph from United States and Wais Mohammad Qarani from Afghanistan. To know more about the top 10 finalists, please visit: https://www.asterguardians.com/.

Speaking on the top 10 finalists and the upcoming award ceremony to be held on 12th May – International Nurses Day, at The Atlantis, Dubai, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “With over 7000 nurses as the main pillar of our organization, we at Aster witness their commitment and compassion every single day. During this pandemic, their critical contribution with dedication and sacrifice, putting their own safety and lives at risk, was brought to the forefront globally. We thought that it is appropriate to institute a global level award for the nurses to recognize the members of this noble profession. With over 24,000 nurses who applied, we are overwhelmed by the response received from different parts of the world for the inaugural edition of Aster Guardians Global Nursing Award. It has been a hard task for the eminent Jury members to shortlist the top 10 extraordinary nurses from the large number of applicants. We wish the finalists nominated in the top 10 all the very best for the final evaluation process.”

While one winner will be awarded the grand prize of USD 250,000, the other nine finalists will receive a monetary award. The final round will consist of public voting for each of the nurses starting from 26th April and in-person interview with the Grand Jury members consisting of Mr. Howard Catton - Chief Executive Officer, International Council of Nurses, Switzerland; Prof. Sheila Tlou - Co-Chairperson, Global HIV Prevention Coalition and Ex - Minister of Health & Member of Parliament – Govt. of Botswana; Prof. James Buchan - Adjunct Professor, WHO Collaborating Centre for Nursing; Mr. Muralee Thummarukudy, Acting Head, Resilience to Disasters and Conflicts Global Support Branch, United Nations Environment Programme, Switzerland; and Dr. Carolyn Gomes, Executive Director, Caribbean Vulnerable Communities Coalition (CVC), Jamaica.

About Aster DM Healthcare

Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 27 hospitals, 118 clinics, 323 pharmacies and 66 labs & patient experience centres in seven countries, including India. We have over 24,350 plus dedicated staff including 3,110 doctors and 7,063 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well."

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lavanya Mandal
Head of PR and Internal Communications, +971528126577
Email: lavanya.mandal@asterdmhealthcare.com
Facebook: https://www.facebook.com/AsterGuardians

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye